Upfront tandem autologous non‐myeloablative allogeneic stem cell transplant in high‐risk multiple myeloma: a long‐term single‐centre experience. Issue 7 (9th July 2022)

• Record Type: Journal Article
• Authors: Nguyen, Phillip C.; Muirhead, Jenny; Tan, Joanne; Kalff, Anna; Bergin, Krystal; Walker, Patricia; Spencer, Andrew
• Is Part Of: Internal medicine journal. Volume 52:Issue 7(2022)
• Page Start: 1263
• Page End: 1267
• Publication Date: 2022-07-09
• Subjects: multiple myeloma -- transplant -- high risk -- allogeneic; Medicine -- Periodicals; 616
• DOI: 10.1111/imj.15842
• Languages: English
• ISSNs: 1444-0903

Abstract

Abstract: The role of upfront non‐myeloablative allogeneic stem cell transplantation (NMA alloSCT) in high‐risk multiple myeloma (HR‐MM) is unclear. We evaluated outcomes of NMA alloSCT following autologous stem cell transplant (ASCT) compared with ASCT alone for newly diagnosed HR‐MM. Two‐year progression‐free survival was improved in the ASCT‐NMA alloSCT group (44% vs 16%; P = 0.035), with a trend for improved overall survival ( P = 0.118). These results suggest that ASCT‐NMA alloSCT can be considered as upfront therapy in HR‐MM.